We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Agentic AI Platform Supports Genomic Decision-Making in Oncology

By LabMedica International staff writers
Posted on 01 Jun 2026

Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. More...

Translating multimodal data into patient-specific, point-of-care guidance remains difficult within routine clinical workflows. To address this gap, a newly upgraded physician platform now embeds next-generation agentic artificial intelligence (AI) to proactively surface genomic insights and generate patient-ready documentation, aiming to streamline decision support in oncology care.

Tempus AI (Chicago, IL, USA) has upgraded its AI-enabled smart physician platform, Tempus Hub, by embedding a next-generation generative AI clinical co-pilot that delivers an agent-first experience for healthcare providers. The upgrade connects the company’s advanced agentic AI directly with real-time patient data within Hub, aligning large language model capabilities with each patient’s diagnostic results to support cancer care decisions. Hub is a secure platform used by thousands of oncologists and care teams to deliver actionable insights at the point of care.

Within Hub, clinicians can access Tempus test orders and results, including guideline-matched therapies, treatment resistance insights, clinical trial opportunities, and longitudinal biomarker tracking for every patient. The new architecture adds proactive, agentic AI that can automatically produce patient overviews and apply deeper analysis to a patient’s Tempus genomic results on the summary page. It also expands into next-step documentation generation, enabling instant creation of patient-specific materials such as prior authorizations and patient messages by pulling directly from Tempus data.

These capabilities are supported by foundational connectivity layers: Edge, which enables real-time connections to electronic health record (EHR) systems and other provider platforms; Locker, which allows providers to store data in a secure, provider‑controlled environment; and Air, which deploys AI models and algorithms in real time at the point of care. Planned iterations include linking Tempus genomics results with the company’s longitudinal patient registry or health information exchange (HIE) data to enable more complex generative AI workflows. Together, these additions are intended to scale how providers utilize, interpret, and act on complex diagnostic insights during routine encounters.

“Our evolution toward an agent-first experience within the Tempus Hub represents a massive win for clinical workflow efficiency,” said Shane Colley, Chief Technology Officer at Tempus. “By bringing our most sophisticated co-pilot intelligence directly into the Hub, we are unlocking the true power of multimodal data to provide seamless, on-demand decision support that meets providers exactly where they are."

Related Links
Tempus AI


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: New findings shows that specific blood proteins are altered long before multiple sclerosis diagnosis, pointing to a potential approach for pre-symptomatic risk assessment (image credit: Adobe Stock)

Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis

Multiple sclerosis (MS) can inflict neurologic damage that is difficult or impossible to repair, and many patients are diagnosed only after disease progression. Identifying at-risk individuals earlier... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.